Nomides caps. 75mg 10 pc

Description

Composition
Active substance:
1 capsule contains: oseltamivir 30 mg, 45 mg or 75 mg.
Product form:
Capsules of 30 mg; 45 mg; 75 mg.
10 capsules in blisters.
Contraindications
Increased sensitivity to oseltamivir phosphate or any component of the formulation, end-stage renal failure (creatinine clearance
Carefully
Pregnancy, lactation.
Dosage
75 mg
Indications
Treatment of influenza in adults and children over the age of 3 years. Prophylaxis of influenza in adults and adolescents aged over 12 years who are at increased risk of infection with the virus (in large collectives, debilitated patients). Prevention of influenza in children older than 3 years.
pharmachologic effect
Pharmacological group:
An antiviral agent.
Pharmacological properties:
Nomides – is an antiviral drug, which includes oseltamivir carboxylate, which inhibits influenza virus A and B. The result of this is suppressed: the release of newly formed viral particles from infected cells and their penetration into the epithelial cells of the respiratory tract and the further spread of the virus in the body.
Nomides is an effective means of prevention and treatment of influenza in adults and children over the age of 3 years. At the beginning of treatment not later than 40 hours after the first symptoms of influenza Nomides significantly shortens the period of clinical manifestations of influenza infection, reduces their weight and reduces the incidence of influenza complications requiring antibiotics (bronchitis, pneumonia, sinusitis, otitis media), shortens the virus isolation from the body.
Following oral administration of oseltamivir phosphate is readily absorbed in the gastrointestinal tract and a highly converted into the active metabolite by the action of hepatic esterases. The concentrations of the active metabolite in the plasma are determined within 30 minutes and reaching almost the maximum level 2-3 hours after ingestion. Not less than 75% of an oral dose reaches the systemic circulation as the active metabolite. Plasma concentrations are proportional to dose and are not dependent on food intake.
Pregnancy and breast-feeding
Not found direct or indirect adverse effects of the drug on pregnancy, embriofetalnoe or postnatal development. During pregnancy and breastfeeding period, oseltamivir is used only if the expected benefit to the mother outweighs the potential risk to the fetus and child.
Conditions of supply of pharmacies
By prescription.
Storage conditions
Store in original manufacturer’s packaging at a temperature not above 25 C. Keep out of reach of children.
Dosing and Administration
The drug oseltamivir taken orally, regardless of the meal or during meal time.
Treatment
The drug should be started no later than 2 days after the development of symptoms. Adults and adolescents aged> 12 years
The recommended daily dose is 150 mg. The drug is administered at a dose of 75 mg (one 75 mg capsule, or one 30 mg capsule + one capsule of 45 mg), 2 times a day orally for 5 days.
Children weighing more than 40 kg or aged> 8 years
Children, who are able to swallow capsules, may also be treated by taking 75 mg (one 75 mg capsule, or one 30 mg capsule + one capsule of 45 mg), 2 times a day for 5 days.
Children aged> 3 years The recommended dosing regimen of oseltamivir capsules 30 and 45 mg.
Body weight: The recommended dose for 5 days
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist